TW200621764A - Substituted hydantoins - Google Patents

Substituted hydantoins

Info

Publication number
TW200621764A
TW200621764A TW094127672A TW94127672A TW200621764A TW 200621764 A TW200621764 A TW 200621764A TW 094127672 A TW094127672 A TW 094127672A TW 94127672 A TW94127672 A TW 94127672A TW 200621764 A TW200621764 A TW 200621764A
Authority
TW
Taiwan
Prior art keywords
substituted hydantoins
compounds
useful
diseases
hydantoins
Prior art date
Application number
TW094127672A
Other languages
English (en)
Chinese (zh)
Inventor
Xin-Jie Chu
Nader Fotouhi
Nicholas John Silvester Huby
Norman Kong
Lee Apostle Mcdermott
John Anthony Moliterni
Zhuming Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of TW200621764A publication Critical patent/TW200621764A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
TW094127672A 2004-08-17 2005-08-15 Substituted hydantoins TW200621764A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60217504P 2004-08-17 2004-08-17
US68299705P 2005-05-20 2005-05-20

Publications (1)

Publication Number Publication Date
TW200621764A true TW200621764A (en) 2006-07-01

Family

ID=35589619

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094127672A TW200621764A (en) 2004-08-17 2005-08-15 Substituted hydantoins

Country Status (16)

Country Link
US (1) US7427635B2 (enExample)
EP (1) EP1781649B1 (enExample)
JP (1) JP4927733B2 (enExample)
KR (2) KR20090006885A (enExample)
AR (1) AR050297A1 (enExample)
AT (1) ATE404556T1 (enExample)
AU (1) AU2005274390B2 (enExample)
BR (1) BRPI0514515A (enExample)
CA (1) CA2576599A1 (enExample)
DE (1) DE602005008986D1 (enExample)
ES (1) ES2313389T3 (enExample)
MX (1) MX2007001846A (enExample)
PL (1) PL1781649T3 (enExample)
RU (1) RU2383542C2 (enExample)
TW (1) TW200621764A (enExample)
WO (1) WO2006018188A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200621766A (en) * 2004-09-17 2006-07-01 Hoffmann La Roche Substituted hydantoins
US7612212B2 (en) 2006-02-22 2009-11-03 Hoffmann-La Roche Inc. Substituted hydantoins
JP2010526848A (ja) * 2007-05-11 2010-08-05 エフ．ホフマン−ラ ロシュ アーゲー 難溶性薬物用の医薬組成物
EP2188276B1 (en) 2007-08-16 2012-03-28 F. Hoffmann-La Roche AG Substituted hydantoins
CN101896469A (zh) * 2007-12-20 2010-11-24 霍夫曼-拉罗奇有限公司 作为mek激酶抑制剂的取代的乙内酰脲类化合物
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
UA105005C2 (uk) * 2008-06-16 2014-04-10 Юніверсіті Оф Теннессі Рісерч Фаундейшн Сполуки для лікування раку
EP2370568B1 (en) 2008-12-10 2017-07-19 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
TW201113280A (en) * 2009-07-03 2011-04-16 Nensius Res As Aminoalkamides for use in the treatment of inflammatory, degenerative or demyelinating diseases of the CNS
CA2789696C (en) 2010-02-25 2017-11-07 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
CA2791738C (en) 2010-03-01 2020-06-09 Gtx, Inc. Aryl imidazolyl compounds for the treatment of cancer
EP2545187B1 (en) 2010-03-09 2018-09-05 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
BR112012027762B1 (pt) 2010-04-28 2018-06-05 Bayer Intellectual Property Gmbh Derivados de cetoheteroarilpiperidina e - piperazina como fungicidas
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
EA202190558A1 (ru) * 2018-09-17 2022-02-03 Янгчжин Фарм. Ко., Лтд. Новые производные тиазола и их фармацевтически приемлемые соли
KR102335637B1 (ko) * 2020-03-13 2021-12-06 영진약품 주식회사 신규한 cdk7 억제 화합물 및 이의 약제학적으로 허용가능한 염
US20230095520A1 (en) * 2020-03-13 2023-03-30 Yungjin Pharm. Co., Ltd. Pharmaceutical composition for preventing or treating cancer comprising azole derivatives or pharmaceutically acceptable salt thereof
KR20210146144A (ko) 2020-05-26 2021-12-03 엘지전자 주식회사 카트부

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770573A (en) * 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
ES2229515T3 (es) 1997-07-01 2005-04-16 Warner-Lambert Company Llc Derivados 4-bromo o 4-yodo del acido fenilamino benzhidroxamico y su uso como inhibidores de la mek.
ATE304011T1 (de) * 2000-05-03 2005-09-15 Hoffmann La Roche Hydantoin-enthaltende glucokinase aktivatoren
JP2004534857A (ja) * 2001-07-19 2004-11-18 フアルマシア・イタリア・エツセ・ピー・アー フェニルアセトアミド−チアゾール誘導体、それらの製造のための方法及び抗癌剤としてのそれらの使用

Also Published As

Publication number Publication date
RU2383542C2 (ru) 2010-03-10
KR20070034635A (ko) 2007-03-28
ATE404556T1 (de) 2008-08-15
KR20090006885A (ko) 2009-01-15
KR100889721B1 (ko) 2009-03-23
AU2005274390A1 (en) 2006-02-23
RU2007109651A (ru) 2008-09-27
WO2006018188A2 (en) 2006-02-23
WO2006018188A3 (en) 2006-05-18
PL1781649T3 (pl) 2009-01-30
EP1781649A2 (en) 2007-05-09
US20060041146A1 (en) 2006-02-23
EP1781649B1 (en) 2008-08-13
CA2576599A1 (en) 2006-02-23
BRPI0514515A (pt) 2008-06-10
ES2313389T3 (es) 2009-03-01
MX2007001846A (es) 2007-03-28
JP4927733B2 (ja) 2012-05-09
DE602005008986D1 (de) 2008-09-25
AU2005274390B2 (en) 2012-01-19
US7427635B2 (en) 2008-09-23
AR050297A1 (es) 2006-10-11
JP2008509950A (ja) 2008-04-03

Similar Documents

Publication Publication Date Title
TW200621766A (en) Substituted hydantoins
HUS2100051I1 (hu) Kompozíciók és eljárások sejtproliferációs rendellenességek kezelésére
WO2006018188A3 (en) Substituted hydantoins
UA101493C2 (ru) Производные азетидина и циклобутана как ингибиторы jak
IL258880A (en) Diarylhydantoin compounds
EA200801362A1 (ru) Пиримидинил бензотиофеновые соединения
EA200870292A1 (ru) Соединения на основе имидазола, композиции, содержащие их, и способы их применения
MX2007012374A (es) Metodos y composiciones para el tratamiento de condiciones relacionadas con cns.
GEP20084420B (en) Use of imidazole compounds for the treatment of neurodegenerative disorders
TW200509892A (en) Novel aminobenzophenone compounds
MX2010004219A (es) Agentes de enlace de cd19 y usos de los mismos.
TW200714590A (en) Heterocyclic inhibitors of MEK and methods of use thereof
TW200631583A (en) Substituted pteridines for the treatment of inflammatory diseases
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
MX2010006331A (es) Hidantoinas sustituidas como inhibidores de cinasa mek.
UA90698C2 (en) Triazole substituted aminobenzophenone compounds
CR8696A (es) Beta-carbolinas utiles para tratar enfermedades inflamatorias
TW200635597A (en) Substituted pteridines for the treatment of inflammatory diseases
TW200724140A (en) Hydantoin compounds
MX2008001982A (es) Compuestos nitro-o, sus composiciones farmaceuticas y sus usos.
TW200633711A (en) Substituted pteridines for the treatment of inflammatory diseases
EA200601607A1 (ru) Сульфонамидные соединения для лечения нейродегенеративных расстройств
TW200734324A (en) Therapeutic agents
MX2007003281A (es) N-etilhidroxietilamina util en el tratamiento de afecciones del sistema nervioso central.
TW200628453A (en) Triazole substituted aminobenzophenone compounds